The UK's most complete GLP-1 guide
Every Question Answered. Every Side Effect Explained.
- How GLP-1 medications work
- Mounjaro vs Wegovy compared
- Injection instructions
- Side effects & solutions
- What to eat on treatment
- FAQs answered
Free tracker included with every download this week
Mounjaro KwikPen 2.5 mg: NHS Starting Dose Explained
The Mounjaro KwikPen 2.5 mg dose is the initial starting point for most UK patients prescribed tirzepatide for weight management. This is a lower dose designed to help your body adjust to the medication before gradually increasing over several weeks. Understanding what the 2.5 mg dose does, how it's used, and what to expect is essential for anyone considering or beginning this prescription weight management treatment through NHS tier 3 specialist services or private prescribing in the UK.
10,000+ calculations today · NHS-aligned thresholds · 100% free
Calculate Your BMI Instantly
Enter your height and weight below. Supports both imperial (stone & lbs) and metric (kg). Results include NHS category, healthy weight range, and ethnicity adjustments.
What Is BMI and Why Does It Matter?
Body Mass Index (BMI) is the most widely used screening tool for assessing whether your weight falls within a healthy range. Used by the NHS, GPs, and weight management services across the UK, BMI provides a quick snapshot of your weight relative to your height. The formula is simple: your weight in kilograms divided by your height in metres squared (kg/m²).
While BMI isn't a perfect measure — it doesn't account for muscle mass, bone density, or fat distribution — it remains the standard first step in identifying potential weight-related health risks including type 2 diabetes, cardiovascular disease, high blood pressure, and certain cancers.
The NHS also recommends adjusted thresholds for people of South Asian, Chinese, or Black African heritage — a BMI of 23 or above is classified as overweight, and 27.5 as obese. Our calculator includes this adjustment as a one-click toggle.
NHS Eligibility and 2.5 mg as the Starting Dose
Mounjaro KwikPen 2.5 mg is prescribed as the initial dose for adults meeting NHS eligibility criteria. You may qualify if you have a BMI of 30 kg/m² or above, or a BMI of 27–29.9 kg/m² with weight-related health conditions such as type 2 diabetes, hypertension, or sleep apnoea. Lower thresholds apply for South Asian, Chinese, Black African, or Black Caribbean adults (BMI 27.5+).
The 2.5 mg KwikPen contains four weekly injections—one month's supply. You stay on this dose for weeks 1–4 while your body adapts. Dose escalation then increases every 4 weeks (5 mg, 7.5 mg, 10 mg, 12.5 mg, then 15 mg maximum) based on tolerability and clinical response. This gradual titration approach, outlined in NICE guidance, helps minimise side effects and improves treatment success.
Use our free BMI calculator above to check if you fall within the eligible range, and try our GLP-1 weight loss calculator to explore potential outcomes at different doses including the 2.5 mg starting point.
Clinically BackedWeight Loss
No appointments. No waiting rooms. Just care — from a UK-regulated online pharmacy.
How It Works
Three simple steps to understand your weight and take action.
Enter your height and weight in our free calculator. Get your BMI, NHS category, healthy weight range, and ethnicity-adjusted thresholds instantly.
If your BMI suggests you're overweight or obese, explore our GLP-1 calculators to project potential weight loss on Mounjaro or Wegovy.
Use our progress tracker to log your weight weekly, visualise your journey with charts, and stay motivated — all stored privately in your browser.
Free Weight Loss Tools & Guides
Everything you need to understand your weight, explore medication options, and track your progress — completely free.
What Happens on Your First 2.5 mg Injection
Your first Mounjaro KwikPen 2.5 mg injection is administered as a subcutaneous injection (under the skin) into your stomach, thigh, or upper arm. The pre-filled KwikPen is easy to use—no mixing or measuring required. Most patients experience mild side effects initially: nausea, loss of appetite, or mild diarrhoea are common in the first few days and typically improve within a week.
During weeks 1–4 on 2.5 mg, your prescriber will monitor how you respond and assess whether you're ready to increase to 5 mg at week 5. This starting dose is deliberately gentle—it's not designed to deliver maximum weight loss, but rather to establish tolerance. Weight loss results at 2.5 mg are modest (typically 3–5% body weight over 4 weeks), but consistency and adherence at this stage set the foundation for successful treatment as doses increase.
- Dual GIP/GLP-1 receptor agonist
- Up to 22.5% body weight loss (SURMOUNT-1)
- Weekly injection, dose escalation over 20+ weeks
- Available via private prescription in the UK
- Doses: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
- GLP-1 receptor agonist
- Up to 15–17% body weight loss (STEP trials)
- Weekly injection, 5-step dose escalation
- NHS & private prescription available
- Doses: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
Mounjaro vs Wegovy: Head-to-Head
A side-by-side comparison of the two most popular GLP-1 weight loss medications available in the UK.
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Active ingredient | Tirzepatide | Semaglutide |
| Avg. weight loss | 15–22.5% | 12–17% |
| Key trial | SURMOUNT-1 (2022) | STEP 1 (2021) |
| Max dose | 15 mg weekly | 2.4 mg weekly |
| Escalation period | 20–32 weeks | 16–20 weeks |
| Administration | Weekly injection (pen) | Weekly injection (pen) |
| NHS availability | Private prescription only | NHS & private |
| Approx. private cost | £150–£250/month | £150–£300/month |
| Common side effects | Nausea, diarrhoea, constipation | Nausea, vomiting, diarrhoea |
Data sourced from SURMOUNT-1 and STEP 1 clinical trials. Costs are approximate and vary by provider. Always consult a prescriber.
Am I Eligible for Weight Loss Medication?
In the UK, eligibility for GLP-1 weight loss medications like Mounjaro and Wegovy is based on your BMI and overall health profile.
- BMI of 30 or above (obese)
- Age 18 or over
- No contraindicated conditions
- Committed to lifestyle changes
- BMI of 27 or above
- Plus type 2 diabetes
- Or high blood pressure
- Or obstructive sleep apnoea
Use our BMI calculator to check whether your BMI falls within the eligible range.
How We Built These Tools
Every calculator and guide on myweightcheck is built with accuracy and transparency in mind. Our BMI calculator uses the standard WHO formula with NHS-aligned category thresholds. Our GLP-1 projections are modelled on published clinical trial data from SURMOUNT and STEP studies.
All data stays on your device. We don't require sign-ups, and we don't store your health information on any server. Your progress tracker saves data locally in your browser using localStorage, so only you can see it.
We're based in the UK and our tools are designed specifically for UK users — supporting stone & lbs by default, referencing NHS guidelines, using NICE-approved medication data, and linking to GPhC-registered pharmacies.
Frequently Asked Questions
Common questions about BMI, weight loss medications, and our free UK tools.
Is Mounjaro KwikPen 2.5 mg available on the NHS in the UK?
Yes, Mounjaro (tirzepatide) is NICE-approved and available through NHS tier 3 specialist weight management services. However, NHS access varies significantly by region—waiting lists can be lengthy. Private prescribing is also available through GPhC-registered online pharmacies following a clinical assessment. Your GP can discuss which route is most appropriate for you.
How do I inject the Mounjaro KwikPen 2.5 mg?
The KwikPen is a pre-filled, single-use device. Remove it from the refrigerator 15–30 minutes before use to allow it to reach room temperature. Pinch the skin at your injection site, insert the needle at a 90-degree angle, and press the button until you hear a click. Hold for 3 seconds, then withdraw. Each pen contains four weekly doses.
What side effects should I expect on 2.5 mg?
Very common side effects include nausea, diarrhoea, constipation, and loss of appetite—especially in the first 1–2 weeks. These usually improve as your body adapts. Seek urgent medical attention if you experience severe stomach pain (possible pancreatitis), serious allergic reactions, or persistent vomiting lasting more than a few hours.
How much weight will I lose on Mounjaro 2.5 mg?
At 2.5 mg, average weight loss is modest—typically 3–5% of body weight over the first 4 weeks. Individual results vary significantly and depend on diet, physical activity, and personal metabolism. This starting dose is designed for tolerance, not maximum weight loss. Greater losses usually occur as doses increase to 5 mg and beyond.
What's the difference between Mounjaro 2.5 mg and Wegovy?
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, while Wegovy (semaglutide) activates GLP-1 only. Mounjaro's dual mechanism may offer stronger appetite suppression. Wegovy's starting dose is 0.25 mg (lower). Both are prescription-only. Your prescriber will advise which is more suitable based on your individual health profile.
Ready to take control of your weight loss journey?
Start with a free BMI check, explore your GLP-1 options, or begin tracking your progress today. No sign-up. No cost. Just results.